Moderna (MRNA)
(Real Time Quote from BATS)
$138.63 USD
+5.73 (4.31%)
Updated May 20, 2024 10:47 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Moderna (MRNA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$136.15 | $310.00 | $60.00 | 2.45% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Moderna comes to $136.15. The forecasts range from a low of $60.00 to a high of $310.00. The average price target represents an increase of 2.45% from the last closing price of $132.90.
Analyst Price Targets (19)
Broker Rating
Moderna currently has an average brokerage recommendation (ABR) of 2.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 2.43 a month ago based on 21 recommendations.
Of the 22 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 36.36% and 4.55% of all recommendations. A month ago, Strong Buy made up 38.1%, while Buy represented 4.76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 9 | 9 | 8 | 9 |
Sell | 1 | 1 | 1 | 1 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.45 | 2.43 | 2.43 | 2.40 | 2.35 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/13/2024 | Evercore Partners | Cory Kasimov | Not Available | Hold |
5/3/2024 | Canaccord Genuity | William Maughan | Hold | Hold |
5/3/2024 | SVB Securities | Mani Foroohar | Strong Sell | Strong Sell |
5/2/2024 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
4/1/2024 | William Blair | Myles R Minter | Hold | Hold |
3/28/2024 | Needham & Company | Joseph R Stringer | Not Available | Hold |
3/28/2024 | Guggenheim Securities | Evan Wang | Hold | Hold |
2/27/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
1/9/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
12/1/2023 | Chardan Capital Markets | Yevgeniya Livshits | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.45 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 22 |
Average Target Price | $136.15 |
LT Growth Rate | 17.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -3.45 |